Navigation Links
Cempra, Inc. to Present at the NIAID Workshop Bridging the Gap - Overcoming Bottlenecks in the Development of Therapeutics for Infectious Diseases
Date:8/6/2012

CHAPEL HILL, N.C., Aug. 6, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP) today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, will present at the NIAID workshop Bridging the Gap – Overcoming  Bottlenecks in the Development of Therapeutics for Infectious Diseases on August 9 to 10 in Rockville, MD. Dr. Fernandes will present how Cempra is working to overcome bottlenecks during the clinical development of one of its clinical candidates, solithromycin. The workshop is planned by the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Diseases, with the goal of helping to advance new therapeutics for infectious diseases through the product development pipeline.

About Cempra, Inc.

Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates have both completed oral Phase 2 clinical trials and seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to utilize its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com.

Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others:  the costs, timing, regulatory review and results of our studies and clinical trials; our need to obtain additional funding and our ability to obtain future funding on acceptable terms; our ability to obtain FDA approval of our product candidates; our dependence on the success of solithromycin and Taksta; our anticipated capital expenditures and our estimates regarding our capital requirements; the possible impairment of, or inability to obtain, intellectual property rights and the costs of obtaining such rights from third parties; the unpredictability of the size of the markets for, and market acceptance of, any of our products, including solithromycin and Taksta; our ability to produce and sell any approved products and the price we are able realize for those products; our ability to retain and hire necessary employees and to staff our operations appropriately; our ability to compete in our industry; innovation by our competitors; and our ability to stay abreast of and comply with new or modified laws and regulations that currently apply or become applicable to our business.  The reader is referred to the documents that we file from time to time with the Securities and Exchange Commission.

Investor and Media Contacts:
Robert E. Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226
Robert.flamm@russopartnersllc.com

Andreas Marathovouniotis
Russo Partners, LLC
(212) 845-4235
Andreas.marathis@russopartnersllc.com


'/>"/>
SOURCE Cempra Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cempra, Inc. to Report Second Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on August 8, 2012
2. Cempra, Inc. to Present at the Global Technology Community 9th Anti-Infectives Partnering and Deal-Making Conference
3. Cempra, Inc. to Report First Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on May 10, 2012
4. Savient Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
5. Frost & Sullivan: Improving Economies in Indonesia and Vietnam Present Strong Growth Potential in Healthcare
6. Synergy Pharmaceuticals to Present Scientific Posters at the Upcoming Gastroenterology Society Meetings in the U.S. and Europe
7. Verenium To Present At The Jefferies 2012 Global Industrial And Aerospace & Defense Conference
8. The Gomez Law Firm Launches New Website Representing Victims Of Defective Stryker Hip Replacement Systems
9. ADVENTRX Pharmaceuticals to Present at 1st Annual Sickle Cell Disease Therapeutics Conference
10. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2012 Financial Results
11. TMG Health To Present Kip Piper at Thought Leadership Dinner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, a ... active in the biopharmaceutical, nutraceutical, and aquacultural feed ... of its lead drug candidates, AGR131.  This drug ... cytokine from the blood of patients suffering from ... inflammatory bowel disease. ...
(Date:8/2/2017)... and BENTON, Ky. , Aug. 2, 2017   Marshall County ... its environmental services (ES) team to proactively reduce the risk of hospital-acquired infections (HAIs). The ... disinfection robot that uses UVC light energy to kill deadly pathogens such as C. ... Tru-D SmartUVC ... Tru-D in action in ...
(Date:8/1/2017)... 1, 2017   CerSci Therapeutics , a non-opioid ... , has received notice from the National Institute ... Health (NIH) that it has been awarded a Direct-to-Phase ... $650,000 in 2017 with an additional $1,000,000 to follow ... Drug application of their lead non-opioid drug candidate CT-044 ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... Summer days spent with ... family-owned supermarket, has put together suggestions for enjoying the season of sunshine. Add trying ... everyone in the family can join in on the fun. , Try Something ...
(Date:8/16/2017)... ... August 16, 2017 , ... Blue Health Intelligence (BHI) announced today ... Officer. Dr. Spiro brings over 30 years of clinical, healthcare IT, value-based care, and ... analytics solutions. , “I am thrilled to welcome Dr. Spiro to BHI,” said ...
(Date:8/16/2017)... , ... August 16, 2017 , ... Greenfield Advisors is ... in the U.S. for the second year in a row. The Inc. 5000 list ... three years. , “To be on the list once is a great accomplishment, but ...
(Date:8/16/2017)... ... 2017 , ... The Data Council, the leading provider of ... by Advantage Solutions. The Data Council’s IX-ONE platform is the Specialty, Natural ... suppliers, brokers, distributors and retailers. The Data Council will become a part of ...
(Date:8/16/2017)... ... August 16, 2017 , ... For the second year, the ... to educate the public on the impact of concussions. Brooke Mills, student and ... Concussion Awareness Day. , Brooke is working diligently is to raise awareness of ...
Breaking Medicine News(10 mins):